Governor Andrew Cuomo’s office announced last week, that a large biopharmaceutical company will be investing millions of dollars with the aim of creating a manufacturing and development center at Pfizer’s large campus in Pearl River.
The company, Protein Sciences Corp. will manufacture Flublok, an influenza vaccine currently under final review by the U.S. Food and Drug Administration. The vaccine is expected to be approved sometime in January.
Initially Protein Sciences’ operation is expected to employ 50 full time workers through its lease of two buildings on the Pfizer campus. However according to Cuomo’s office, it is possible that that number could reach as high as 150 within 10 years.
“We are thrilled to be expanding our operations into New York and laying roots in Rockland County,” said Protein Sciences CEO Manon Cox. “The state and local government have provided invaluable assistance, without which this transaction would not have been viable.”
Protein Sciences will receive $2 million in tax credits from Empire State Development, New York’s economic development agency. The credit is an incentive for the company, with terms to create 100 new jobs before 2018 and maintain those employment levels through 2023.
New York State Senator David Carlucci praised the plan. “Job creation is taking hold here in Rockland County,” he posted on his Facebook page. “This is yet another example of how New York State is working to foster innovation and create good paying jobs right here in the Hudson Valley.”
Pharmaceutical Manufacturing Comes back to Pearl River added by dskriloff on
View all posts by dskriloff →
You must be logged in to post a comment Login